17 April 2024
17 April 2024
Teva will manage the commercialisation of the product in the US.
The company’s first quarter reported sales grew 2.3% to $21.4bn from $20.8bn in Q1 2023.
The FDA has cleared Spinogenix’s Phase II trial of SPG601, as the European Commission grants orphan drug status to zatolmilast.
Medincell is eligible to receive up to $1.9bn in milestone payments, plus royalties on global product sales.
The funding will accelerate AI product development for lung cancer research and enhance clinical trial efficiency.
Acorda’s closure date is set for 15 June, as Merz Therapeutics looks set to acquire the biotech’s once-prolific assets.
Boehringer Ingelheim announced consistent growth across its human pharma sales and R&D investments in 2023.
The move expedites and enhances research, development and quality-control works linked to advanced therapies.
Merging industry-leading business intelligence & award-winning journalism, this is an unrivalled opportunity for engagement with B2B professionals across a network of 40+ leading media websites.
Steer your business strategy with key data and insights from our latest market research reports and company profiles. Not ready to buy? Start small by downloading a sample report first.
Give your business an edge with our leading industry insights.
